Maintenance of remission in ulcerative colitis. Effect of an orally absorbed mast cell stabilizer.
PRD-92 a well-absorbed mast cell stabilizer was examined in patients with ulcerative colitis by a double-blind controlled trial. Forty-three patients who were in clinical remission or PRD-92 for six months. Relapses occurred in 42% of patients on PRD-92 and 24% on sulfasalazine. PRD-92 has a less prophylactic effect than sulfasalazine in ulcerative colitis.
D000328:Adult; D000368:Aged; D001578:Benzopyrans / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000534:rehabilitation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012008:Recurrence; D012075:Remission, Spontaneous; D012107:Research Design; D012460:Sulfasalazine / Q000627:therapeutic use; D013997:Time Factors
D001578:Benzopyrans; D010919:Placebos; D012460:Sulfasalazine; C010685:PR-D-92